In addition to 5 products and 13 indications launched commercially and 5 NDAs accepted for review, Henlius has conducted over 20 clinical studies for 13 products and 11 immuno-oncology combination therapies worldwide. HANLIKANG (rituximab injection), the first product of Henlius, has been approved by the National Medical Products Administration (NMPA) as China's first biosimilar. The second product HANQUYOU (trastuzumab, Zercepac® in the EU，Trade names in Australia: Tuzucip® and Trastucip®) is the first Chinese mAb biosimilar approved both in the EU and China, bringing more treatment options to patients with HER2 positive breast and gastric cancer worldwide. In March 2022, the company’s first self-developed innovative monoclonal antibody, HANSIZHUANG (serplulimab injection), was approved by the NMPA for the treatment of Microsatellite Instability-High (MSI-H) solid tumors. Meanwhile, its NDAs for the treatment of squamous non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC) , and esophageal squamous cell carcinoma (ESCC) are under review.